Evidence map›Paper›PMID 38398378›Full record

ReviewJournal of clinical medicine2024

New Perspectives of Therapies in Osteogenesis Imperfecta-A Literature Review.

Alexandru Dinulescu, Alexandru-Sorin Păsărică, Mădălina Carp, Andrei Dușcă, Irina Dijmărescu, Mirela Luminița Pavelescu, Daniela Păcurar, Alexandru Ulici

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
9.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. [Comprehensive considerations for the diagnosis, treatment, and management of osteogenesis imperfecta].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Review
  4. Article
  5. Article
  6. Anti-transforming growth factor-β treatment shows increased bone mass and strength in a novel mouse model for osteogenesis imperfecta type I.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025
    Article
  7. Further Evidence of Early-Onset Osteoporosis and Bone Fractures as a NewInternational journal of molecular sciences · 2025
    Article
  8. Article
  9. Review
  10. What's new in the pediatric spine?Journal of children's orthopaedics · 2025
    Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Alexandru DinulescuDepartament of Pediatrics and Department of Pediatric Orthopedics, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.ORCID 0000-0001-8008-4408
Alexandru-Sorin PăsăricăDepartament of Pediatrics and Department of Pediatric Orthopedics, Emergency Hospital for Children ''Grigore Alexandrescu'', 011743 Bucharest, Romania.
Mădălina CarpDepartament of Pediatrics and Department of Pediatric Orthopedics, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Andrei DușcăDepartament of Pediatrics and Department of Pediatric Orthopedics, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Irina DijmărescuDepartament of Pediatrics and Department of Pediatric Orthopedics, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.ORCID 0000-0002-5814-2082
Mirela Luminița PavelescuDepartament of Pediatrics and Department of Pediatric Orthopedics, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Daniela PăcurarDepartament of Pediatrics and Department of Pediatric Orthopedics, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.ORCID 0000-0002-8604-8691
Alexandru UliciDepartament of Pediatrics and Department of Pediatric Orthopedics, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.ORCID 0000-0003-1018-1506
Carol Davila University of Medicine and Pharmacy · ROClinical Emergency Hospital Bucharest · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: Osteogenesis imperfecta (OI) is a rare skeletal dysplasia characterized as a heterogeneous disorder group with well-defined phenotypic and genetic features that share uncommon bone fragility. The current treatment options, medical and orthopedic, are limited and not efficient enough to improve the low bone density, bone fragility, growth, and mobility of the affected individuals, creating the need for alternative therapeutic agents. (2) Methods: We searched the medical database to find papers regarding treatments for OI other than conventional ones. We included 45 publications. (3) Results: In reviewing the literature, eight new potential therapies for OI were identified, proving promising results in cells and animal models or in human practice, but further research is still needed. Bone marrow transplantation is a promising therapy in mice, adults, and children, decreasing the fracture rate with a beneficial effect on structural bone proprieties. Anti-RANKL antibodies generated controversial results related to the therapy schedule, from no change in the fracture rate to improvement in the bone mineral density resorption markers and bone formation, but with adverse effects related to hypercalcemia. Sclerostin inhibitors in murine models demonstrated an increase in the bone formation rate and trabecular cortical bone mass, and a few human studies showed an increase in biomarkers and BMD and the downregulation of resorption markers. Recombinant human parathormone and TGF-β generated good results in human studies by increasing BMD, depending on the type of OI. Gene therapy, 4-phenylbutiric acid, and inhibition of eIF2α phosphatase enzymes have only been studied in cell cultures and animal models, with promising results. (4) Conclusions: This paper focuses on eight potential therapies for OI, but there is not yet enough data for a new, generally accepted treatment. Most of them showed promising results, but further research is needed, especially in the pediatric field.

Indexed as

anti-RANKL antibodiesanti-TGF-β antibodiesgene therapyinhibition of eIF2α phosphatase enzymesmesenchymal stem cellsosteogenesis imperfectarecombinant PTHsclerostin inhibition

Identifiers

PMID38398378
PMCPMC10888533
OpenAlexW4391821720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.